Overall Survival with Bortezomib (V)/Melphalan (M)/Prednisone (P)/ Thalidomide (T) and VT Maintenance versus VMP for Newly Diagnosed MM


Overall Survival with Bortezomib (V)/Melphalan (M)/Prednisone (P)/ Thalidomide (T) and VT Maintenance versus VMP for Newly Diagnosed MM
Slides from a presentation at ASH 2012 and transcribed comments from a recent interview with Kenneth C Anderson, MD (3/29/13)

Palumbo A et al. Overall survival benefit for bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in newly diagnosed multiple myeloma patients. Proc ASH 2012;Abstract 200.

Dr Anderson is Kraft Family Professor of Medicine at Harvard Medical School, Director of the Jerome Lipper Multiple Myeloma Center and Director of the LeBow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute in Boston, Massachusetts.